TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company
focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity
Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016
Healthcare Conference and the ROTH 3rd Annual Healthcare Day.
| |
|
| Jefferies 2016 Healthcare Conference |
|
| Date: |
|
Wednesday, June 8 |
| Time: |
|
8:00am Eastern Daylight Time |
| Location: |
|
Grand Hyatt Hotel, New York City |
| Webcast: |
|
http://wsw.com/webcast/jeff97/adhd
|
| |
|
| ROTH 3rd Annual Healthcare
Day |
|
| Date: |
|
Wednesday, June 22 |
| Location: |
|
The Dorchester Hotel, London UK |
| |
|
|
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of
MDX, a proprietary drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the
Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
